Kyverna Therapeutics, Inc. Common Stock (KYTX) — Financial Flexibility Index
Kyverna Therapeutics, Inc. Common Stock (KYTX) has a Financial Flexibility Index of -0.54x as of December 2025. Free cash flow of $-33.52 Million (operating CF $-33.53 Million minus capex $5.00K) represents -1% of total liabilities ($61.55 Million). Also explore KYTX net assets growth trend to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Kyverna Therapeutics, Inc. Common Stock Financial Flexibility Index (2021–2025)
Historical Financial Flexibility Index trend for Kyverna Therapeutics, Inc. Common Stock across 5 annual periods. Check Kyverna Therapeutics, Inc. Common Stock liquidity resilience to evaluate the company's liquid asset resilience ratio.
Annual Financial Flexibility Index for Kyverna Therapeutics, Inc. Common Stock (2021–2025)
Year-by-year free cash flow to debt coverage for Kyverna Therapeutics, Inc. Common Stock. For the full company profile including market capitalisation, see how much is Kyverna Therapeutics, Inc. Common Stock worth.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.50x | $-153.71 Million | $-153.71 Million | $61.55 Million | ▲ +15.2% |
| 2024 | -2.94x | $-112.05 Million | $-114.25 Million | $38.06 Million | ▼ -47.9% |
| 2023 | -1.99x | $-51.79 Million | $-52.41 Million | $26.02 Million | ▼ -14.0% |
| 2022 | -1.75x | $-35.34 Million | $-36.11 Million | $20.25 Million | ▼ -1002.2% |
| 2021 | -0.16x | $-20.87 Million | $-22.16 Million | $131.74 Million | — |